May 8–9, 2018

Stanford University, Palo Alto, California

REGISTRATION WILL BE OPENING ON FEBRUARY 1ST

THE LIGHT STORY


The LIGHT Forum: Leaders In Global Healthcare and Technology is a conference designed for leaders from a broad cross-section of executives and top policy makers in the health-care field to discuss the latest developments, challenges and opportunities shaping the industry. Working hand in hand with leading thinkers from Silicon Valley, the event provides attendees with an ideal forum for networking as well as rigorous analysis and foresight.

The global health-care industry is at a turning point. The rise of personalized medicine, fundamental change in how healthcare is paid for, an explosion of data, and the transformation of the industry into a “global game” are just some of the most powerful forces roiling the landscape. At the same time, dramatic advances in artificial intelligence mean that big data and so-called “deep learning” offer the potential of unprecedented insight and market power for those who figure out how to harness these tools.

The initiative has been conceived to help the world’s top healthcare executives seize the moment.

Light Stanford Linguistics

+

2018 EDITION SPEAKERS


Click on the speaker's photo to read his/her bio.

  • Peter_Brabeck-High-resized-1

    Peter Brabeck-Letmathe

    Chairman Emeritus, Nestlé S.A.

    Olivier Brandicourt

    Olivier Brandicourt

    CEO, Sanofi

    sp-Cheesbrough-Paul

    Paul Cheesbrough

    Chief Technology Officer, 21st Century Fox

  • Bill George

    Bill George

    Senior Fellow, Harvard Business School; Former Chairman and Chief Executive Officer, Medtronic; Author of Discover Your True North

    Jeff George_11

    Jeff George

    Former Division Head & CEO, Sandoz and Alcon, Novartis Group

    sp-Glasspool-John

    John Glasspool

    Former Executive VP, Head of Corporate Strategy & Customer Operations at Baxalta

  • James Greenwood

    James Greenwood

    President and CEO of the Biotechnology Innovation Organization (BIO)

    George Halvorson

    George Halvorson

    CEO and Chair Institute for InterGroup Understanding; Former Chair and CEO of Kaiser Permanente

    Bob Hormats

    Robert Hormats

    Vice Chairman, Kissinger Associates, Inc.

  • Omar Ishrak

    Omar Ishrak

    Chairman & CEO, Medtronic

    Joseph Jimenez

    Joseph Jimenez

    CEO, Novartis

    sp-Kindler-Jeff

    Jeffrey B. Kindler

    CEO, Centrexion Corporation

  • Kevin Lobo

    Kevin A. Lobo

    Chairman and CEO, Stryker

    sp-Lonsdale-Joe

    Joe Lonsdale

    Partner, 8VC;
    Founder, Palantir and Addepar

    Andrew Maas_Website_1

    Andrew Maas

    Co-Founder & Co-Chief Scientist at Roam Analytics

  • Mark McClellan

    Mark McClellan, M.D.

    Director, Margolis Center for Health Policy at Duke University

    George Mitchell

    Senator George Mitchell

    Partner & Chairman Emeritus,
    DLA Piper

    sp-Orszag-Peter

    Peter Orszag

    Vice Chairman of Investment Banking & Global Co-Head of Healthcare, Lazard Freres & Co. LLC

  • Thomas Pickering

    Ambassador Tom Pickering

    Vice Chairman, Hills & Company

    Potts-Chris

    Chris Potts

    Professor, Stanford University Department of Linguistics

    sp-Robinson-Peter

    Peter M. Robinson

    Murdoch Research Fellow,
    Hoover Institution

  • Amir Rubin

    Amir Rubin

    President and CEO, One Medical

    Sahami-Mehran

    Mehran Sahami

    Professor, Stanford Artificial Intelligence Laboratory

    sp-schaeffer-s

    Susan Schaeffer

    Editor, BioCentury

  • John-Thornhill-photo

    John Thornhill

    Innovation Editor, The Financial Times

    Alex Turkeltaub_Web

    Alex Turkeltaub

    CEO and Co-Founder, Roam Analytics

Peter_Brabeck-High-resized-1
Peter Brabeck-Letmathe
Chairman Emeritus, Nestlé S.A.

On April 6th, 2017, Peter Brabeck-Letmathe was appointed Chairman Emeritus of Nestlé S.A. Previously, he led the Nestlé Group from 1997 to 2008, first as CEO till 2005, and then as Chairman and CEO. In April 2008, he handed over the office of CEO and remained Chairman of the Board of Nestlé S.A.

Born in 1944 in Austria, Peter Brabeck-Letmathe graduated from the University of World Trade in Vienna with a degree in Economics. After joining the Nestlé Group in 1968, he spent a significant part of his career in Latin America, before being transferred to Nestlé’s International Headquarter in Vevey as Senior Vice-President. Appointed Executive Vice-President as of 1992 and Member of the Executive Board, he was in charge of the Strategic Business Units, Marketing & Sales, as well as Corporate Communications.

BOARD MANDATES
Peter Brabeck-Letmathe serves as Vice-Chairman of the Foundation Board of the World Economic Forum. He is an Independent Director of Delta Topco (Formula 1) and serves as member of the Advisory Board of Amrop. He also served as a Board Member of Roche, Credit Suisse, L’Oréal and Exxon Mobil Corporation. In addition, he was Chairman of the 2030 Water Resources Group, a Public Private Partnership.

AWARDS
Peter Brabeck-Letmathe has received several awards, including the Austrian Cross of Honour for services to the Republic of Austria, "La Orden Mexicana del Águila Azteca", "La Orden Francisco de Miranda" conferred by the republic of Venezuela, and the Schumpeter Prize for outstanding contribution in disruptive Innovation. The University of Alberta (Canada) conferred an Honorary Degree of Doctor of Laws on him. Recently, Mr. Brabeck-Letmathe has been inducted into the American Advertising Federation’s “Hall of Fame”.

Olivier Brandicourt
Olivier Brandicourt
CEO, Sanofi

Olivier Brandicourt joined Sanofi in April 2015 as Chief Executive Officer.

Prior to joining the Group, Brandicourt was Chief Executive Officer of Bayer Healthcare AG (2013-2015). From 2000 through to 2013, he held a series of leadership positions at Pfizer culminating as a member of the Executive Leadership Team and as President and General Manager of the Emerging Markets and Established Products business units.

Brandicourt started his career in the pharmaceutical industry in 1987 as a Medical Director for the Region Africa at Warner-Lambert/Parke-Davis, where he held other senior positions in medical and marketing before being appointed General Manager of Canada. He also spent eight years with the Institute of Infectious and Tropical Diseases at the Pitié-Salpêtrière Hospital in Paris with a focus on malaria research in West and Central Africa and two years in the Republic of Congo as a doctor.

Olivier Brandicourt studied medicine in Paris where he specialized in Infectious Diseases and Tropical Medicine (University of Paris V) and holds an Advanced Degree in Cellular and Immunological Pathophysiology from the Paris Descartes University. He also holds a Master’s Degree in Biology (University of Paris XII).

sp-Cheesbrough-Paul
Paul Cheesbrough
Chief Technology Officer, 21st Century Fox

Paul Cheesbrough is Chief Technology Officer for 21st Century Fox. In this role Mr. Cheesbrough oversees the company’s technology strategy and operations on a global basis. He joined 21st Century Fox in December 2016.

Prior to this, he served as Chief Technology Officer for News Corp, overseeing the enterprise technologies and digital products and platforms across the business as well as the technology investment portfolio. In this role he led significant change across the business, moving it to more cloud-based technologies and putting innovation and engineering at the heart of the organizations owned by the company.

Before joining News Corp, Mr. Cheesbrough served as Chief Information Officer at the Telegraph Media Group, where he pioneered the development of a wide range of new digital products. Prior to the Telegraph, he was the Controller of Digital Media for the BBC, having started his career in IBM within its media division as a software engineer.

Bill George
Bill George
Senior Fellow, Harvard Business School; Former Chairman and Chief Executive Officer, Medtronic; Author of Discover Your True North

Bill George is a senior fellow at Harvard Business School, where he has taught leadership since 2004. He is the author of: Discover Your True North and The Discover Your True North Fieldbook, Authentic Leadership, True North, Finding Your True North, 7 Lessons for Leading in Crisis and True North Groups.

Mr. George is the former chairman and chief executive officer of Medtronic. He joined Medtronic in 1989 as president and chief operating officer, was chief executive officer from 1991-2001, and board chair from 1996-2002. Earlier in his career, he was a senior executive with Honeywell and Litton Industries and served in the U.S. Department of Defense.

Mr. George currently serves as a director of Goldman Sachs. He has served recently on the boards of ExxonMobil, Novartis, Target Corporation, Minnesota’s Destination Medical Center Corporation and the World Economic Forum USA. Bill is currently a trustee of the Mayo Clinic, and has served as board chair for Allina Health System, Abbott-Northwestern Hospital, United Way of the Greater Twin Cities, and Advamed.

In April 2014 the Franklin Institute awarded him the Bower Award for Business Leadership. He was elected to the National Academy of Engineering in 2012. He has been named one of "Top 25 Business Leaders of the Past 25 Years" by PBS; "Executive of the Year-2001" by the Academy of Management; and "Director of the Year-2001-02" by the National Association of Corporate Directors. Mr. George is a CNBC Contributor and has made frequent appearances on television and radio.

He received his BSIE with high honors from Georgia Tech, his MBA with high distinction from Harvard University, where he was a Baker Scholar, and honorary PhDs from Georgia Tech, Mayo Medical School, University of St. Thomas, Augsburg College and Bryant University. During 2002-03 he was professor at IMD International and Ecole Polytechnique in Lausanne, Switzerland, and executive-in-residence at Yale School of Management.

He and his wife Penny reside in Minneapolis, Minnesota.

Jeff George_11
Jeff George
Former Division Head & CEO, Sandoz and Alcon, Novartis Group

Jeff served on the Novartis Group Executive Committee from 2008 to 2016, first as Division Head and CEO of Sandoz (2008-2014), Novartis’s $10 billion generic pharmaceuticals and biosimilars subsidiary, and then as Division Head and CEO of Alcon (2014-2016), Novartis’s then $10 billion eye care subsidiary. Prior to this, he was Head of Emerging Markets at Novartis Pharmaceuticals for the Middle East, Africa, Southeast Asia and CIS, after serving as Vice President and Head of Western & Eastern Europe for Novartis Vaccines.

In both of his divisional CEO roles, Jeff was responsible for leading over 25,000 associates globally across more than 160 countries and had primary line leadership and management responsibility for all functions, regions, and franchises. Sandoz is the second-largest generic pharmaceuticals company globally. Sandoz sales grew by over $1.7 billion during his tenure to $9.2 billion in 2013 and became the global leader in biosimilars, while attaining #1 positions globally in generic dermatologics, ophthalmics, and injectables. Alcon was the largest ophthalmology company globally in 2016, operating across the ophthalmic pharmaceuticals, surgical and vision care segments. Acquired for $52 billion in 2011, Alcon was restructured in 2016, with the $4 billion pharma business moving into Novartis Pharmaceuticals.

Before joining Novartis, Jeff was Senior Director of Strategic Planning and Business Development at Gap Inc., where he led growth, licensing, and European expansion efforts for one of its apparel divisions. Prior to this he was an Engagement Manager at McKinsey & Company in San Francisco. Jeff has also worked in emerging markets private equity in South Africa and in Washington, D.C.

Jeff holds an MBA from Harvard Business School and a master’s degree from Johns Hopkins University’s School of Advanced International Studies (SAIS), where he studied international economics and emerging markets political economy and was awarded the John W. Watzek fellowship. He received his B.A. in international relations, magna cum laude and Phi Beta Kappa, from Carleton College.

Jeff serves on the Board of Directors at Roam Analytics, a Stanford- and venture-backed Silicon Valley machine learning and artificial intelligence healthcare data analytics firm, where he has been a strategic advisor to the CEO since 2015. He served on the Board of Directors for AdvaMed from 2014 to 2016 and is a member of the Young President’s Organization (YPO). He was twice named to Fortune’s “40 under 40” list of up-and-coming leaders. He has lived in seven countries on four continents and is married with two daughters. He enjoys running, coaching soccer, live music, international affairs, meditation, and working with multiple non-profits both nationally and in the Dallas area.

sp-Glasspool-John
John Glasspool
Former Executive VP, Head of Corporate Strategy & Customer Operations at Baxalta

As a seasoned pharmaceutical executive with over 25 years of experience in the industry, Royston John Glasspool has extensive experience in multiple line and staff functions in the US, UK, Europe, and global markets through his roles of increasing responsibility at Scotia Pharmaceuticals, Johnson & Johnson, Novartis, Baxter, and Baxalta. This experience has helped him architect innovative approaches to patient-centered drug development within the companies he has served, such as the P5 planning process and patient access approach. He has led franchises with over $6B in sales and has launched over 10 products. He is regularly invited to expert panels and also serves on the Board of Directors of the Biotechnology Industry Organization (BIO). John holds 2 patents and has degrees in politics and international relations from the University of Staffordshire, UK, and in business administration from Oxford Brookes University with a focus on international marketing. Before joining the pharmaceutical industry, John owned a restaurant and small hotel.

John lives in Hingham, MA with his wife Susan, daughter Samantha, and cat Sushi.

James Greenwood
James Greenwood
President and CEO of the Biotechnology Innovation Organization (BIO)

James C. Greenwood is President and CEO of the Biotechnology Innovation Organization (BIO) in Washington, D.C. BIO represents 1,000 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 countries worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, and industrial & environmental biotechnology products. BIO also produces the annual BIO International Convention, the world's largest annual gathering of the biotechnology industry, as well as other major investor and business conferences across the world.

Greenwood represented Pennsylvania's Eighth District in the U.S. House of Representatives from 1993 to 2005. Since 2005, his deep relationships on Capitol Hill and knowledge of politics and policy have substantially raised BIO’s profile and enhanced the organization’s advocacy work. During his time in Congress, he was a senior member of the Energy and Commerce Committee and widely viewed as a leader on health care and the environment. He crafted legislation to reform the Food and Drug Administration, and he led the fight in Congress to allow stem-cell research to be conducted by U.S. scientists to treat disease.

From 2001 to 2004, Greenwood served as Chairman of the Energy and Commerce Committee Subcommittee on Oversight and Investigation with oversight authority over issues in the full Committee's jurisdiction. He led hard-hitting investigations into corporate governance at Enron, Global Crossing and WorldCom; terrorist threats to our nation's infrastructure; and waste and fraud in federal government agencies.

Prior to his election to Congress, Greenwood served six years in the Pennsylvania General Assembly (1981-86) and six years in the Pennsylvania Senate (1987-1992). Greenwood graduated from Dickinson College in 1973 with a B.A. in Sociology. From 1977 until 1980, he worked as a caseworker with abused and neglected children at the Bucks County Children and Youth Social Service Agency. Mr. Greenwood is married with three children and resides in Upper Makefield, Pennsylvania.

George Halvorson
George Halvorson
CEO and Chair Institute for InterGroup Understanding; Former Chair and CEO of Kaiser Permanente

George Halvorson is Chair and CEO of the Institute for InterGroup Understanding. He has served for more than 30 years as CEO of six different health care delivery and financing organizations in the U.S., and he helped start similar health care organizations in several other countries. Most recently Halvorson served as Kaiser Permanente Chairman and CEO from 2002 – 2014, before retiring as CEO in July 2013, and Chairman in January 2014.

Halvorson is currently Chair of the First 5 Commission for Children and Families for the State of California. In 2013 Governor Jerry Brown appointed Halvorson to a four-year term as Chair, and then re-appointed him to another four years in 2017. The Commission uses roughly $500 million each year — raised from tobacco taxes — to provide support and education to children in California from birth to 5 years old.

Halvorson is a member of the Right Start Commission for Children in the State of California, and an advisory council member for the Too Small To Fail Commission. He currently serves as a member of the CEO Advisory Council for the Ready Nation coalition.

The Institute for InterGroup Understanding works on issues of racism, prejudice, discrimination, misogyny, and InterGroup stress and conflict. Halvorson has written four books on those topics, which are all available as teaching materials from the Institute.

Electronic versions of the InterGroup books can be downloaded or read directly from the Institute for InterGroup Understanding website at no charge. (Hard copies of the books are available at Amazon.com.)

The books and the Institute website explain how our instinctive behaviors steer us into conflict in various intergroup settings, and outline and explain the steps we should take to create intergroup Peace.

Halvorson recently revised The Art of InterGroup Peace — his book on achieving intergroup peace around the world — into its Third Edition, which can be downloaded for free at the Institute for InterGroup Understanding website.

Three Key Years, one of Halvorson’s most recent titles, is paramount to early childhood education, and explains the importance of positive interactions between caring adults and infants in their first three years of life. Halvorson also designed threekeyyears.org, a website dedicated to educating new parents on the simple steps they should take in a child’s first three years to improve their lives forever.

His final health care book, Don’t Let Health Care Bankrupt America, explains how to use market forces and extensive care support tools to make health care significantly better and more affordable. The book describes actual tools and processes Halvorson used while running the largest private care system in America.

Bob Hormats
Robert Hormats
Vice Chairman, Kissinger Associates, Inc.

Robert Hormats is Vice-Chairman of Kissinger Associates Inc. the New York based strategic international consulting firm that assesses and navigates emerging market geopolitical and macroeconomic risk for its clients. Previously Bob served as Under Secretary of State for Economic, Energy and Environmental Affairs from September 2009 to July 2013.

Before this Bob was vice chairman of Goldman Sachs (International) for 25 years. Earlier, Bob served as Assistant Secretary of State for Economic and Business Affairs from 1981 to 1982, Ambassador and Deputy U.S. Trade Representative from 1979 to 1981, and Senior Deputy Assistant Secretary for Economic and Business Affairs .He served as a senior staff member for International Economic Affairs on the National Security Council from 1969 to 1977, where he was senior economic advisor to Dr. Henry Kissinger, General Brent Scowcroft and Dr. Zbigniew Brzezinski.

Bob has worked extensively in Western Europe, China, India, Russia, the Middle East and South East Asia. His areas of expertise and experience include international trade and investment, intellectual property, foreign investment in the US, protection of trade secrets and global energy issues.

Bob is currently a board member of the American Tower Corporation, Chairman of the Board of the RAND Center for Asia and Pacific Policy (CAPP) and member of the Investment Committee of Tiedemann Wealth Management Company. He has been a visiting lecturer at Princeton and Columbia universities and at the University of California at San Diego, and has served on the Board of Visitors of the Fletcher School of Law and Diplomacy of Tufts University and the Dean’s Council of the John F. Kennedy School of Government at Harvard. He is also a member of the Council on Foreign Relations and the Economic Club of New York.

Omar Ishrak
Omar Ishrak
Chairman & CEO, Medtronic

Omar Ishrak has served as Chairman and Chief Executive Officer of Medtronic since June 2011. Medtronic is the world’s leading medical technology company, with $29 billion in annual revenue, and operations reaching more than 160 countries worldwide. Medtronic offers technologies and solutions to treat a wide range of medical conditions, including cardiac and vascular diseases, respiratory, neurological and spinal conditions, diabetes, and more. The Medtronic Mission is to alleviate pain, restore health, and extend life for millions of people around the world.

Since joining Medtronic, Omar has focused the company on three core strategies of Therapy Innovation, Economic Value and Globalization. These three strategies form the basis for Medtronic’s efforts to partner with its customers to drive high quality patient outcomes, expand patient access to healthcare, and lower costs in health care systems around the world. In 2014, Omar engineered the acquisition of Covidien, a $10 billion global manufacturer of surgical products and supplies. The acquisition of Covidien was the largest medical technology acquisition in the history of the industry.

Omar joined Medtronic from General Electric Company, where he spent 16 years, most recently as President and CEO of GE Healthcare Systems, a $12 billion division of GE Healthcare, with a broad portfolio of diagnostic, imaging, patient monitoring and life support systems. Omar also served as an Officer and a Senior Vice President of GE. Earlier in his career, Omar amassed 13 years of technology development and business management experience, holding leadership positions at Diasonics/Vingmed, and various product development and engineering positions at Philips Ultrasound.

He grew up in Bangladesh, and earned a Bachelor of Science degree and Ph.D. in Electrical Engineering from the University of London, King's College. He is also a Fellow of King’s College.

Omar currently serves as co-chair of the World Economic Forum’s Health and Healthcare Community, which includes global leaders focused on shaping the future of health and healthcare. Key areas of focus for this community include promoting healthy behaviors, better management of future pandemics/epidemics, increasing global access to care, and increasing value in healthcare systems to advance healthcare delivery and improve patient outcomes.

Omar is a member of the Board of Directors of Intel, a global technology company with more than $59 billion in annual revenue. Omar is a member of the Board of Trustees of the Asia Society, the leading educational organization dedicated to promoting mutual understanding and strengthening partnerships among peoples, leaders and institutions of Asia and the United States in a global context. He is also a member of the Minnesota Public Radio Board of Trustees.

Joseph Jimenez
Joseph Jimenez
CEO, Novartis

From 2010 to 2018, Joseph Jimenez held the position of Chief Executive Officer (CEO) of Novartis, one of the world’s leading pharmaceutical companies. Under his leadership, Novartis developed one of the largest pipelines of self-originated drugs in the industry, driven by a strong commitment to R&D. Mr. Jimenez also transformed the company’s portfolio to focus on innovative patented medicines under Novartis Pharmaceuticals and Novartis Oncology, generics under Sandoz, and eye care devices under Alcon.

Prior to serving as CEO of Novartis, Mr. Jimenez held the position of Division Head, Novartis Pharmaceuticals. He joined Novartis in 2007 as Division Head, Novartis Consumer Health. Before that, Mr. Jimenez served as president and CEO of the North American and European businesses for the H.J. Heinz Company.

Mr. Jimenez is currently a member of the Board of Directors of General Motors Company. Additionally, he served on the Board of Directors of Colgate-Palmolive Company from 2009 to 2015, and of AstraZeneca PLC, from 2002 to 2007.

He graduated in 1982 with a bachelor’s degree from Stanford University and in 1984 with a Master of Business Administration from the University of California, Berkeley, both in the United States.

sp-Kindler-Jeff
Jeffrey B. Kindler
CEO, Centrexion Corporation

Jeff Kindler is a healthcare executive, investor and advisor who has held leadership positions at some of the world's most recognized companies. With more than three decades of experience, Kindler is a leading expert in pharmaceuticals and other health care sectors; corporate legal matters including regulation, litigation, compliance and crisis management; brand and franchise management; board and corporate governance; and executive leadership.

Currently, Kindler serves as CEO of Centrexion Corporation, a privately held biotherapeutics company developing pain therapies; Executive Chairman of vTv, a pharmaceutical development company; Venture Partner at Lux Capital, a leading venture capital firm; Managing Director at Starboard Capital Partners, a private equity firm; and a principal in and advisor to a number of privately held health care firms and sponsors. He is also Global Chair of the GLG Institute, a membership-based learning community for leading executives, and serves as a member of President Obama's Management Advisory Board.

Kindler serves on the boards of a number of publicly and privately held health care companies as well as several not-for-profit institutions including Tufts University.

Kindler was formerly the Chairman and Chief Executive Officer of Pfizer, the world's largest research-based biopharmaceutical company, which he joined in January 2002. As CEO, Kindler led Pfizer’s $68 billion merger and acquisition of Wyeth, diversified Pfizer’s product portfolio, improved its R&D pipeline, and reshaped the company’s commercial, innovation, and leadership models to drive growth and cultural change. He joined Pfizer as Executive Vice President and General Counsel and, prior to his appointment as CEO in July 2006, he served as a Vice Chairman of the company, responsible for Pfizer’s corporate affairs including worldwide legal, regulatory and patent matters as well as a range of public affairs and communications functions, and serving as a member of the four-person executive committee overseeing global business operations.

While at Pfizer, Kindler worked with former President Bill Clinton to help bring medicines to impoverished patients in the developing world through public-private pharmaceutical partnerships. He also represented the pharmaceutical industry in U.S. government healthcare reform efforts, helping to increase access to affordable medicines while preserving an environment in which pharmaceutical firms can discover and develop innovative treatments.

In 1996, Kindler joined McDonald's Corporation as Executive Vice President and General Counsel, responsible for both legal and corporate affairs, and then moved into line management as President of Partner Brands, which included overseeing franchise, operations and marketing efforts for restaurant brands such as Boston Market, Chipotle Mexican Grill, Donato’s Pizza, and Pret a Manger. Before joining McDonald’s Corporation, Kindler was Vice President of Litigation and Legal Policy of the General Electric Company.

Prior to GE, Kindler practiced civil and criminal litigation as a partner at the Washington D.C. firm of Williams & Connolly. He began his career as an attorney at the Federal Communications Commission and served as a law clerk to Judge David L. Bazelon of the U.S. Court of Appeals of the D.C. Circuit and later as law clerk to U.S. Supreme Court Justice William J. Brennan, Jr.

Kindler earned his BA in 1977 from Tufts University summa cum laude and his JD in 1980 from Harvard magna cum laude, where he was an editor of the Harvard Law Review.

Kevin Lobo
Kevin A. Lobo
Chairman and CEO, Stryker

Kevin A. Lobo was appointed Chairman of the Board on July 22, 2014 in addition to his responsibilities as Chief Executive Officer of Stryker Corporation, which he assumed on October 1, 2012. Mr. Lobo joined Stryker in 2011, and had previously been Group President of Orthopaedics. Mr. Lobo serves on the Board of Directors for Parker Hannifin Corporation, the global leader in motion and control technologies. He is also a board member of the Advanced Medical Technology Association (AdvaMed), the Business Leaders for Michigan and United Way for Kalamazoo/Battle Creek regions, and is a member of the Business Roundtable and the Business Council. Mr. Lobo has a broad business career that includes executive positions in general management and finance. After holding finance positions with KPMG, Unilever and Kraft Canada he spent eight years with Rhone-Poulenc, including roles based in Europe as Worldwide Corporate Controller of the chemical spin-out, Rhodia, and General Manager of Specialty Phosphates EMEA. He then spent eight years at Johnson & Johnson, including CFO of McNeil Consumer Healthcare and Ortho Women’s Health & Urology, President of J&J Medical Products Canada and President of Ethicon Endo Surgery.

Mr. Lobo's extensive global business and leadership experience across multiple industries, including healthcare, enables him to provide valuable insight to the Board regarding the Company's operations and the strategic planning initiatives necessary to meet the demands of the changing environment. As the sole member of management on our Board, he provides management's business perspectives and the necessary link to our day-to-day operations.

sp-Lonsdale-Joe
Joe Lonsdale
Partner, 8VC;
Founder, Palantir and Addepar

Joe Lonsdale is a partner at 8VC, a San Francisco-based venture capital fund. He was an early institutional investor in many notable companies including Wish, Oculus, Illumio, Virgin Hyperloop One, Blend, RelateIQ, ZenReach, Color Genomics and uBiome, and in 2016 and 2017 was the youngest member of the Forbes 100 Midas List.

Joe is a co-founder of Palantir, a multi-billion dollar global software company best known for its work in defense and finance. Most recently, he was a founding partner at Formation 8, the precursor fund to 8VC, which manages over 1.5 billion USD and is one of the top performing private funds. Before that, he founded Addepar, a leading wealth management technology platform, and OpenGov. He is also a founder of Affinity and Anduin. Previously, Joe was an early executive at Clarium Capital, which he helped grow into a large global macro hedge fund. He also worked with PayPal while he was at Stanford.

Joe received a B.S. in Computer Science from Stanford in 2003. He often lectures and writes on entrepreneurship, technology, and public policy.

Andrew Maas_Website_1
Andrew Maas
Co-Founder & Co-Chief Scientist at Roam Analytics

Andrew graduated with a PhD in Computer Science from Stanford University in 2015, advised by Andrew Ng and Dan Jurafsky. His research focuses on large scale deep learning to solve some of the most challenging problems in data analytics and forecasting, speech recognition, natural language processing, and computer vision. Andrew has consulted for Coursera, where he built biometric classifiers; for other clients he has developed recommendation systems for TV content and unsupervised similarity discovery algorithms for legal patents. Andrew received his B.S. from Carnegie Mellon in 2009. In 2017, he was voted by Forbes as a top 30 UNDER 30 in Enterprise Technology.

Mark McClellan
Mark McClellan, M.D.
Director, Margolis Center for Health Policy at Duke University

Mark McClellan, MD, PhD, is the Robert J. Margolis Professor of Business, Medicine, and Policy, and Director of the Margolis Center for Health Policy at Duke University. He is a physician- economist who focuses on quality and value in health care including payment reform, real-world evidence and more effective drug and device innovation. He is former administrator of the Centers for Medicare & Medicaid Services and former commissioner of the U.S. Food and Drug Administration, where he developed and implemented major reforms in health policy. He was previously Senior Fellow at the Brookings Institution and a faculty member at Stanford University.

George Mitchell
Senator George Mitchell
Partner & Chairman Emeritus,
DLA Piper

Senator George Mitchell has had a long and distinguished career. He served for several years as Chairman of DLA Piper, now Chairman Emeritus. Before that he served as a federal judge; as Majority Leader of the United States Senate; as Chairman of peace negotiations in Northern Ireland which resulted in an agreement that ended an historic conflict; and most recently as U.S. Special Envoy to the Middle East. In 2008 Time Magazine described him as one of the 100 most influential people in the world. Senator Mitchell is the author of five books. His most recent books are a memoir entitled The Negotiator: Reflections on an American Life, published in May 2015 and A Path To Peace, published in November 2016.

sp-Orszag-Peter
Peter Orszag
Vice Chairman of Investment Banking & Global Co-Head of Healthcare, Lazard Freres & Co. LLC

Peter Orszag joined Lazard as a Managing Director and Vice Chairman of Investment Banking in May 2016. He is based in New York.

Prior to joining Lazard, Mr. Orszag was with Citigroup (since 2011), where he was Vice Chairman of Corporate and Investment Banking at Citigroup, and Chairman of Citi’s Financial Strategy and Solutions Group. He is also a nonresident Senior Fellow in Economic Studies at the Brookings Institution. Mr. Orszag previously served as a Distinguished Visiting Fellow at the Council on Foreign Relations (2010-2015). He was the Director of the Office of Management and Budget (2009-2010), serving in President Barack Obama’s cabinet, and Director of the Congressional Budget Office (CBO) (2007-2008). Before leading the CBO, Mr. Orszag served as Director of The Hamilton Project (generating innovative solutions to support broad-based economic growth) and the Retirement Security Project (promoting retirement security amongst moderate- and lower-income families).

Princeton University, B.A., summa cum laude in Economics; London School of Economics, Ph.D., Economics (Marshall Scholar)

Thomas Pickering
Ambassador Tom Pickering
Vice Chairman, Hills & Company

Ambassador Pickering is Vice Chairman of Hills & Company, an international consulting firm providing advice to U.S. businesses on investment, trade, and risk assessment issues abroad, particularly in emerging market economies. He retired in 2006 as senior vice president international relations for Boeing. He has had a career spanning five decades as a U.S. diplomat, serving as under secretary of state for political affairs, ambassador to the United Nations, ambassador to Russia, India, Israel, Nigeria, Jordan and El Salvador. He also served on assignments in Zanzibar and Dar es Salaam, Tanzania. He holds the personal rank of Career Ambassador, the highest in the U.S. Foreign Service. He has held numerous other positions at the State Department, including executive secretary and special assistant to Secretaries Rogers and Kissinger and assistant secretary for the bureau of oceans, environmental and scientific affairs. He is based in Washington, DC.

Potts-Chris
Chris Potts
Professor, Stanford University Department of Linguistics
Chris Potts is Professor of Linguistics and, by courtesy, of Computer Science at Stanford, and Director of the Center for the Study of Language and Information (CSLI) at Stanford. In his research, he develops computational models of linguistic reasoning, emotional expression, and dialogue. He is the author of the 2005 book The Logic of Conventional Implicatures as well as numerous scholarly papers in linguistics and natural language processing.
sp-Robinson-Peter
Peter M. Robinson
Murdoch Research Fellow,
Hoover Institution

Peter M. Robinson is the Murdoch Research Fellow at the Hoover Institution, where he writes about business and politics, edits Hoover's quarterly journal, the Hoover Digest, and hosts Hoover's video series program, Uncommon Knowledge™.

Robinson is also the author of three books: How Ronald Reagan Changed My Life (Regan Books, 2003); It's My Party: A Republican's Messy Love Affair with the GOP, (Warner Books, 2000); and the best-selling business book Snapshots from Hell: The Making of an MBA (Warner Books, 1994; still available in paperback).

In 1979, he graduated summa cum laude from Dartmouth College, where he majored in English. He went on to study politics, philosophy, and economics at Oxford University, from which he graduated in 1982.

Robinson spent six years in the White House, serving from 1982 to 1983 as chief speechwriter to Vice President George Bush and from 1983 to 1988 as special assistant and speechwriter to President Ronald Reagan. He wrote the historic Berlin Wall address in which President Reagan called on General Secretary Mikhail Gorbachev to "tear down this wall!"

After the White House, Robinson attended the Stanford University Graduate School of Business. (The journal he kept formed the basis for Snapshots from Hell.) He graduated with an MBA in 1990.

Robinson then spent a year in New York City with Fox Television, reporting to the owner of the company, Rupert Murdoch. He spent a second year in Washington, D.C., with the Securities and Exchange Commission, where he served as the director of the Office of Public Affairs, Policy Evaluation, and Research. Robinson joined the Hoover Institution in 1993.

The author of numerous essays and interviews, Robinson has published in the New York Times, Red Herring, and Forbes ASAP, the Wall Street Journal, and National Review Online. He is the editor of Can Congress Be Fixed?: Five Essays on Congressional Reform (Hoover Institution Press, 1995).

In 2005, Robinson was elected to serve as a Trustee of Dartmouth College.

Robinson lives in northern California with his wife, their children and their dog, Crusoe.

His research papers are available at the Hoover Institution Archives.

Amir Rubin
Amir Rubin
President and CEO, One Medical

Amir Dan Rubin has sought to make significant positive impacts on health care throughout his career. He serves as President and CEO of One Medical, the leading membership-based, technology-enabled, national primary care organization focused on transforming health care.

Amir previously served as an EVP at UnitedHealth Group’s Optum division, where he served as a divisional CEO focused on helping to make the health system work better for everyone. Amir also previously served as President and CEO at Stanford Health Care—the academic health system affiliated with Stanford University—where he helped raise patient experience and quality scores to the highest levels in the nation, grow a regional network of care settings, and advance digital health and corporate partnerships in the heart of Silicon Valley. Amir also previously served as COO for UCLA Health System, COO for Stony Brook University Hospital, AVP at Memorial Hermann Health System, and management consultant with APM.

Amir holds MBA and MHSA degrees from the University of Michigan, and a BA from the University of California, Berkeley. He has also been awarded the EY Entrepreneur of the Year Award in Northern California for large companies.

Sahami-Mehran
Mehran Sahami
Professor, Stanford Artificial Intelligence Laboratory

Mehran Sahami is a Professor (Teaching) and Associate Chair for Education in the Computer Science department at Stanford University. He is also the Robert and Ruth Halperin University Fellow in Undergraduate Education. Prior to joining the Stanford faculty in 2007, he was a Senior Research Scientist at Google for several years. His research interests include computer science education, machine learning, and web search. He has published numerous papers and has over 20 patent filings on a variety of topics including machine learning, data analytics, web search, recommendation engines in social networks, and email spam filtering that have been deployed in commercial applications.

sp-schaeffer-s
Susan Schaeffer
Editor, BioCentury

Susan serves as Editor of BioCentury. She has been reporting and commenting on the biopharmaceutical industry for 13 years, covering drug discovery and development, corporate strategy and finance, and regulation and policy as it affects multiple stakeholders in the biomedical ecosystem. Her work has been cited in regulatory filings and has recently influenced biopharma executives to lobby for legislative changes necessary to enable greater experimentation with pricing models designed to make innovation more affordable to healthcare systems.

She was previously Senior Editor in charge of Product Discovery & Development coverage from 2010 through 2012. She was Managing Editor of BioCentury and BioCentury Extra from 2004 through 2010. She joined BioCentury in 2003 after 10 years as an editor in the consumer packaged goods sector, including work with international strategy consultants Kurt Salmon Associates.

John-Thornhill-photo
John Thornhill
Innovation Editor, The Financial Times

John was appointed the Innovation Editor on February 2016. Prior to that John has been the deputy editor at the Financial Times since September 2012. He was appointed Financial Times’ news editor, based in London on the main news desk, in January 2009. Prior to this he spent four years in Paris as the editor of the European edition of the Financial Times.

Joining the FT in 1988 as a graduate trainee, Thornhill has been the Paris bureau chief, world news editor, Asia editor, Moscow bureau chief and a Lex columnist.

John founded and runs the FT's 125 executive forum, which holds monthly meetings for senior executives from a range of industries. Previous speakers have included Bill Gates, Jack Dorsey, Ana Botin, and Mark Carney.

In his spare time, John is a keen cyclist and plays chess. He also takes his long-suffering son to support Sunderland football club.

Alex Turkeltaub_Web
Alex Turkeltaub
CEO and Co-Founder, Roam Analytics

Alex is the Co-Founder and Chief Executive of Roam. Prior to Roam, Alex co-founded and was the Chief Executive of Frontier Strategy Group (FSG), a venture-backed data and analytics company focused on emerging markets, which currently serves over 250 leading multinationals. Alex and his family immigrated to the United States from the Soviet Union in 1988; he holds BA and MA degrees in International Relations from Stanford University and a JD from the Yale Law School.

2018 EDITION PROGRAM


View event schedule below.

Tuesday, May 8, 2018
6pm
Cocktails and hors d'oeuvres
Venue: Cantor Arts Center, Stanford University, Palo Alto

7pm
Keynote Conversation: Understanding the Global Context In the Age of Nationalism
Venue: Cantor Arts Center, Stanford University, Palo Alto

Wednesday, May 9, 2018
8:00am - 9:00am
Networking Breakfast
Venue: Stanford University – The Frances C. Arrillaga Alumni Center

9:00am - 9:10am
Welcoming Remarks
Venue: Stanford University – The Frances C. Arrillaga Alumni Center

9:10am – 10:00am
Opening Plenary
Venue: Stanford University – The Frances C. Arrillaga Alumni Center

10:00am – 10:30am
Networking Break
Venue: Stanford University – The Frances C. Arrillaga Alumni Center

10:30am – 11:25am
Plenary
Venue: Stanford University – The Frances C. Arrillaga Alumni Center

11:25am – 11:45am
In Conversation: Healthcare and Technology Leaders In Interactive Discussion
Venue: Stanford University – The Frances C. Arrillaga Alumni Center

11:45am – 12:45pm
Lunch and Networking
Venue: Stanford University – The Frances C. Arrillaga Alumni Center

12:45pm – 1:30pm
Plenary
Venue: Stanford University – The Frances C. Arrillaga Alumni Center

1:30pm – 2:20pm
Plenary
Venue: Stanford University – The Frances C. Arrillaga Alumni Center

2:20pm – 3:15pm
Networking Break
Venue: Stanford University – The Frances C. Arrillaga Alumni Center

3:15pm – 4:10pm
Plenary
Venue: Stanford University – The Frances C. Arrillaga Alumni Center

4:10pm – 5:00pm
Closing Plenary
Venue: Stanford University – The Frances C. Arrillaga Alumni Center

NEWS / PRESS


    • $100

    • 105 UPMC Innovates: Lessons Learned from LIGHT Forum `17

    • News — May 22, 2017

      UPMC Innovates: Lessons Learned from LIGHT Forum `17

      UPMC HealthBeat - Representatives from UPMC earlier this month attended the inaugural Leaders in Global Healthcare and Technology (LIGHT) Forum at Stanford University’s campus in Palo Alto, California...


      View
    • Register
    • $100

    • 110 In-Depth: AI in Healthcare- Where we are now and what’s next

    • News — May 19, 2017

      In-Depth: AI in Healthcare- Where we are now and what's next

      MobiHealthNews - The problem we are trying to solve is one of productivity,” said Andy Slavitt, the former acting administrator of the Centers for Medicare and Medicaid Services said during the Light Forum.


      View
    • Register
    • $100

    • 115 The Inaugural LIGHT Forum Explored the Fundamental Transformation of Healthcare through the Power of Machine Learning and Artificial Intelligence

    • Press Release — May 18, 2017

      The Inaugural LIGHT Forum Explored the Fundamental Transformation of Healthcare through the Power of Machine Learning and Artificial Intelligence

      Healthcare Facilities Today - At the heart of the Forum was the healthcare industry’s shift from selling products to offering solutions — moving towards a system founded on value and outcomes...


      View
    • Register
    • $100

    • 120 Technology is the tool to spur a healthcare revolution

    • News — May 15, 2017

      Technology is the tool to spur a healthcare revolution

      Financial Times - How AI can be further applied to the sector was the subject of the LIGHT Forum at Stanford last week.The forum’s recurring themes were that new technologies could help people take more responsibility for their own health...


      View
    • Register
    • $100

    • 125 Bloomberg Interview – Alex Turkeltaub

    • Video — May 15, 2017

      Roam Analytics CEO Alex Turkeltaub Interviewed on Bloomberg

      Bloomberg - Alex Turkeltaub co-founder and CEO of ROAM Analytics talks about the rise of AI at the LIGHT Forum in Stanford, California.


      View
    • Register
    • $100

    • 140 Bloomberg Interview – Peter Orszag

    • Video — May 12, 2017

      Peter Orszag Says ‘Math Doesn’t Work’ on GOP Health Bill

      Bloomberg - Peter Orszag, former director of the Office of Management and Budget, discusses the prospects for the GOP health bill with Bloomberg's Mike McKee


      View
    • Register
    • $100

    • 145 Bloomberg Interview – Gray Davis

    • Video — May 12, 2017

      Gray Davis on GOP Health-Care Bill, California’s Economy

      Bloomberg - Former California Governor Gray Davis discusses the GOP health-care bill and California's economy.


      View
    • Register
    • $100

    • 150 How Trump could bring drug prices down

    • News — May 12, 2017

      How Trump could bring drug prices down

      Washington Post - Mulvaney explained at the LIGHT Forum at Stanford University that drugmakers receive a “tremendous giveaway” from Medicare's prescription drug benefit.


      View
    • Register
    • $100

    • 155 A Top Trump Official Just Flunked The Jimmy Kimmel Test

    • News — May 12, 2017

      A Top Trump Official Just Flunked The Jimmy Kimmel Test

      HuffPost - Mulvaney, made the comments during the LIGHT Forum in response to a question about the “Jimmy Kimmel Test.”


      View
    • Register
    • $100

    • 160 Press Release – May 12

    • Press Release — May 12, 2017

      The Inaugural LIGHT Forum Explored the Fundamental Transformation of Healthcare through the Power of Machine Learning and Artificial Intelligence

      Over 250 global health and technology leaders attended the first-ever LIGHT Forum, focused on the transformational impact of data, artificial intelligence (AI) and machine learning (ML) on the global healthcare system....


      View
    • Register
    • $100

    • 165 Bloomberg Interview – Sir Martin Sorrell

    • Video — May 11, 2017

      WPP CEO Sees Amazon as Search Threat to Google

      Bloomberg - Martin Sorrell, CEO at WPP PLC, discusses the changes tech is bringing about in the ad industry. He speaks with Bloomberg's Michael McKee from the LIGHT Summit at Stanford University


      View
    • Register
    • $100

    • 170 Bloomberg Interview – Joe Lonsdale

    • Video — May 11, 2017

      Joe Lonsdale Sees Tech and Health Care Intersecting

      Bloomberg - Joe Lonsdale, 8VC founding partner, discusses tech's impact on healthcare with Bloomberg's Mike McKee


      View
    • Register
    • $100

    • 175 Mulvaney Agrees With ‘Jimmy Kimmel Test’

    • News — May 11, 2017

      Mulvaney Agrees With ‘Jimmy Kimmel Test’

      Washington Examiner - Mulvaney was asked by a member of the audience at the Light Forum at Stanford University in Palo Alto, Calif., if he agreed.


      View
    • Register
    • $100

    • 180 Trump and Obama budget chiefs spar over Obamacare replacement

    • News — May 11, 2017

      Trump and Obama budget chiefs spar over Obamacare replacement

      Washington Examiner - Mulvaney, President Trump's budget chief, and Orszag, who held the role for a time under former President Barack Obama, sparred Thursday at the Light Forum.


      View
    • Register
    • $100

    • 185 WPP’s Sorrell: Amazon Search Threat To Google

    • News — May 11, 2017

      WPP's Sorrell: Amazon Search Threat To Google

      Mediapost - At the LIGHT Summit, Sorrell said the group discussed the rise of Amazon because the company "is certainly a threat to Google in search."


      View
    • Register
    • Press Release

    • 190 Press Release – May 04

    • Press Release — May 04, 2017

      LIGHT Forum Reveals Final Speaker Lineup

      The upcoming LIGHT Forum 2017 on 10-11 May, will convene more than 200 high-level executives, medical technologists, and policymakers in global health and technology, to explore the impact and implications of AI and machine learning on health outcomes and business models...


      View
    • Register

CONTACT


Contact for LIGHT Forum 2018

aqila@roaminsight.com